TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET

Company Participants

Corey Davis - IR, LifeSci Advisors

Harlan Weisman - CEO

Zamaneh Mikhak - Chief Medical Officer

Kirk Coleman - CFO

Conference Call Participants

Jonathan Aschoff - ROTH MKM

Justin Walsh - JonesTrading

Daniel Carlson - Tailwinds

Operator

Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.

I will now turn the call over to our host, Corey Davis of LifeSci Advisors. You may begin your conference.

Corey Davis

Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals third quarter 2023 corporate update and earnings conference call. With me on the line this afternoon, are Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals; Dr. Zamaneh Mikhak, Chief Medical Officer; and Kirk Coleman, Chief Financial Officer.

Before we get started, I would like to remind everyone that this call will contain forward-looking statements, including, without limitation, statements about the anticipated timing of achievement of clinical milestones, the potential to see positive effects in our Phase 2 studies, the number of treated patients necessary to make decisions in regards to moving to Phase 3 studies, the market opportunity for our product candidates, and the expected timeframe for funding operations with cash and cash equivalents.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in all of our findings with the U.S. Securities and Exchange Commission, including the Risk Factors section of our 2022 Annual Report on Form 10-K filed with the SEC.

And now, it’s my pleasure to turn the call over to Dr. Harlan Weisman. Go ahead, Harlan?

Harlan Weisman

Thank you, Corey. And good afternoon, everyone. And thank you for joining us for our third quarter 2023, corporate update and earnings conference call. Last quarter, we detailed the considerable progress that we've made across a number of key areas in our ongoing Phase 2 studies of TFF VORI and TFF TAC. Based on these accomplishments and subsequent progress, we continue to expect initial clinical data from the Phase 2 studies by year end. Assuming results from both trials are positive, we believe these initial data will serve as a major catalyst for our company by providing the strongest evidence to-date of how Thin Film Freezing can improve a drug safety and efficacy in two rare disease patient populations.